Discovery of Adjuvants that Direct T-cell Fates for Improved Safety and Efficacy in Vaccines Against Influenza and Tuberculosis

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: AARON  ESSER-KAHN
Organization: UNIVERSITY OF CHICAGO
Fiscal Year: 2024
Award: $1,989,733
Funding agency: National Institute of Allergy and Infectious Diseases

The offeror proposes to discover adjuvants with two sets of unique properties – (1) directing T cell fates and (2) improving the response to mRNA vaccines. This will be accomplished by screening novel immune-potentiators that direct the innate immune response of the original vaccine or adjuvant to induce new immune phenotypes. The goal will be to discover new adjuvant systems that (1) selectively direct T cell fates toward TFH, TH17, TH1, and TH2; and (2) modify the cytokine profile of mRNA vaccinations toward safer and more effective responses while maintaining and improving antibody levels.

Terms: <Adjuvant><Agonist><Antibodies><Cell Body><Cells><Contractor><Derivation><Derivation procedure><Flu vaccination><Formulation><Goals><Ha antigen><Immune><Immunes><In Vitro><In vivo analysis><Influenza Vaccines><Influenza immunization><Influenza vaccination><Innate Immune Response><Libraries><M tuberculosis infection><M. tb infection><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MTB infection><Modeling><Molecular><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><Pathway interactions><Phenotype><Property><Prophylactic vaccination against influenza><Proteins><RNA immunization><RNA vaccination><RNA vaccine><RNA-based vaccine><Safety><Signal Pathway><System><T-Cells><T-Lymphocyte><TB infection><Tuberculosis><Vaccination><Vaccines><cytokine><disseminated TB><disseminated tuberculosis><drug-like chemical><drug-like compound><drug-like molecule><flu immunisation><flu vaccine><flu virus vaccine><improved><in vivo><in vivo evaluation><in vivo testing><infection due to Mycobacterium tuberculosis><influenza virus vaccination><influenza virus vaccine><mRNA immunization><mRNA vaccination><mRNA vaccine><mRNA-based vaccine><mouse model><murine model><novel><pathway><predict responsiveness><predicting response><response><screening><screenings><thymus derived lymphocyte><tuberculosis infection><tuberculous spondyloarthropathy><vaccination against influenza><vaccine against flu><vaccine against influenza>